Oncotalks hematology videos and news

Srdan Verstovsek, MD, PhD; Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial​

Srdan Verstovsek, MD, PhD from the MD Anderson Cancer Center, Houston, VS is commenting on the publication: Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial

Blood (2019) 134 (Supplement_1): 2947.

https://doi.org/10.1182/blood-2019-128101

Related items

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

Prof. Michelino DeLaurentiis, MD, PhD from the National Cancer Institute Fondazione G. Pascale is commenting on his abstract "DeLaurentiis M. et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol 37, 2019 (suppl; abstr 1041)", which was presented at ASCO 2019 in Chicago
ASCO , Kisqali Channel , Lithuania , Albania , Slovenia
00:03:07
EHA 2019 Jeroen Janssen, MD, PhD

EHA 2019 Jeroen Janssen, MD, PhD

Jeroen Janssen MD, PhD from the Amsterdam UMC, Amsterdam, The Netherlands is commenting on the abstract COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML) & COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA Reference: EHA Library. Kew S. Jun 15, 2019; 267467Link to abstract: https://library.ehaweb.org/eha/2019/24th/267467/sam.kew.combination.of.asciminib.plus.nilotinib.28nil29.or.dasatinib.28das29.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dasciminib
EHA , Latvia , Lithuania , Estonia , Albania
00:05:04
ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

Prof. Piotr Rutkowski, MD, PhD from the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw is commenting on the abstract: "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507", which was presented at ASCO 2019 in Chicago
ASCO , Lithuania , Hungary , Albania
00:06:31